乙型肝炎肝硬化患者营养状况及肌少症发生率调查*

doi:10.3969/j.issn.1672-5069.2024.06.024

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (6): 895-898.doi: 10.3969/j.issn.1672-5069.2024.06.024

乙型肝炎肝硬化患者营养状况及肌少症发生率调查^*

魏唯, 初丽敏, 王超, 吴明, 平东兰, 池冰

050021 石家庄市第五医院公共卫生科(魏唯,平东兰);药剂科(王超);石家庄市第三医院老年医学科(初丽敏);静配中心(吴明);河北医科大学第二医院感控科(池冰)

收稿日期:2024-03-05 出版日期:2024-11-10 发布日期:2024-11-07
通讯作者: 平东兰,E-mail:490866910@qq.com
作者简介:魏唯,女,35岁,医学硕士,主治医师。E-mail:ww2024666@126.com
基金资助:
^*河北省医学科学研究重点计划项目(编号:20241965);中国博士后科学基金资助项目(编号:2019M651063)

Prevalence of nutrition and sarcopenia in patients with hepatitis B-induced liver cirrhosis

Wei Wei, Chu Limin, Wang Chao, et al

Department of Public Health, Fifth Hospital, Shijiazhuang 050021, Hebei Province, China

Received:2024-03-05 Online:2024-11-10 Published:2024-11-07

摘要/Abstract

摘要： 目的探讨乙型肝炎肝硬化患者营养状况及肌少症发生的危险因素。方法 2019年1月～2023年12月我院收治的乙型肝炎肝硬化患者156例,采用主观综合性营养评估法(SGA)进行营养风险筛查,使用生物电阻抗分析法(BIA)测量四肢骨骼肌肌肉质量(ASM),计算相对骨骼肌质量指数(ASMI),诊断肌少症。采用多因素Logistic回归分析影响乙型肝炎肝硬化患者发生肌少症的因素。结果本组156例肝硬化患者营养不良发生率为59.0%,肌少症发生率为29.5%,其中39例Child-Pugh A级组营养不良和肌少症发生率分别为20.5%和7.7%,48例B级分别为50.0%和25.0%,69例C级分别为87.0%和44.9%,组间差异(P<0.05); 46例肌少症组年龄、BMI、血清ALB和SGA评分分别为(64.1±12.5)岁、(19.3±2.2)kg/m²、(24.1±3.9)g/L和(21.3±3.4)分,与110例非肌少症组【分别为(54.7±11.2)岁、(23.9±3.0)kg/m²、((34.3±4.8)g/L和(28.7±4.0)分】比,差异有统计学意义(P<0.05);Logistic回归分析显示,BMI(OR=0.683)、血清ALB(OR=0.631)和SGA评分(OR=0.653)均为显著影响乙型肝炎肝硬化患者肌少症发生的独立危险因素(P<0.05)。结论乙型肝炎肝硬化患者伴有营养不良较普遍,肌少症发生风险较高。了解风险因素,做好早期筛查可能指导及时处理。

关键词: 肝硬化, 营养状况, 肌少症, 风险因素

Abstract: Objective The aim of this study was to investigate prevalence of nutrition and sarcopenia in patients with hepatitis B-induced liver cirrhosis (LC). Methods 156 patients with hepatitis B-induced LC were encountered in our hospital between January 2019 and December 2023, subjective global assessment (SGA) was applied to screen nutritional risk, and sarcopenia was diagnosed based on criteria proposed out by Asian Working Group for Sarcopenia 2019 (AWGS2019). Multivariate Logistic regression analysis was used to predict risk factors for sarcopenia. Results Of 156 patients in our series, incidence of malnutrition was 59.0% and incidence of sarcopenia was 29.5%, and they were 20.5% and 7.7% in 39 patients with Child-Pugh class A, 50.0% and 25.0% in 48 patients with class B and 87.0% and 44.9% in 69 patients with class C, significantly different among them (P<0.05); age, basic mass index (BMI), serum albumin level and SGA score in 46 patients with sarcopenia were (64.1±12.5)yr, (19.3±2.2)kg/m², (24.1±3.9)g/L and (21.3±3.4) points, significantly different as compared to [(54.7±11.2)yr, (23.9±3.0) kg/m², ((34.3±4.8)g/L and (28.7±4.0)point, all P<0.05] in 110 patients without sarcopenia; multivariate Logistic regression analysis showed that BMI(OR=0.683), serum albumin level (OR=0.631) and SGA score (OR=0.653) were all risk factors for occurrence of sarcopenia in patients with LC (P<0.05). Conclusion Malnutrition is common in patients with hepatitis B-induced LC, and the risk of sarcopenia is also relatively high. Clinicians should take these incidents into consideration and deal with as early as possible.

Key words: Liver cirrhosis, Malnutrition, Sarcopenia, Risk factors

魏唯, 初丽敏, 王超, 吴明, 平东兰, 池冰. 乙型肝炎肝硬化患者营养状况及肌少症发生率调查^*[J]. 实用肝脏病杂志, 2024, 27(6): 895-898.

Wei Wei, Chu Limin, Wang Chao, et al. Prevalence of nutrition and sarcopenia in patients with hepatitis B-induced liver cirrhosis[J]. Journal of Practical Hepatology, 2024, 27(6): 895-898.

参考文献

[1] Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet, 2021, 398(10308):1359-1376.
[2] Moon AM, Singal AG, Tapper EB. Contemporaryepidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol, 2020, 18(12):2650-2666.
[3] GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol, 2020, 5(3):245-266.
[4] 马琳,贾继东. 肝硬化患者营养不良、肌少症和衰弱的临床研究进展. 肝脏,2021,26(7):717-720.
[5] Aby ES, Saab S. Frailty,sarcopenia, and malnutrition in cirrhotic patients. Clin Liver Dis, 2019, 23(4):589-605.
[6] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[7] Cederholm T, Jensen GL, Correia MITD, et al. GLIM criteria for the diagnosis of malnutrition-a consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle, 2019,10(1):207-217.
[8] 吴国豪.实用临床营养学.上海:复旦大学出版社,2006:3-7.
[9] Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr, 1987, 11(1):8-13.
[10] 崔华,王朝晖,吴剑卿,等. 老年人肌少症防控干预中国专家共识(2023). 中华老年医学杂志,2023,42(2):144-153.
[11] European Association for the Study of the Liver. EASLclinical practice guidelines on nutrition in chronic liver disease. J Hepatol, 2019, 70(1):172-193.
[12] Dumont C, Wuestenberghs F, Lanthier N, et al. Malnutrition is highly prevalent in hospitalized cirrhotic patients and associates with a poor outcome. Acta Gastroenterol Belg, 2022, 85(2):311-319.
[13] Siddiqui ATS, Parkash O, Hashmi SA. Malnutrition and liver disease in a developing country. World J Gastroenterol, 2021, 27(30):4985-4998.
[14] 杨晓玲,张素梅.SGA、MNA和NRS2002评估失代偿期肝硬化患者营养状态应用价值分析.实用肝脏病杂志,2020,23(1):70-73.
[15] Boga S, Yildirim AE, Ucbilek E, et al. The effect of sarcopenia and serum myokines on prognosis and survival in cirrhotic patients: a multicenter cross-sectional study. Eur J Gastroenterol Hepatol, 2022, 34(12):1261-1268.
[16] Zeng X, Shi ZW, Yu JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle, 2021, 12(6):1948-1958.
[17] Lai JC, Tandon P, Bernal W, et al. Malnutrition,frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74(3):1611-1644.
[18] Gümüşsoy M, Atmş V, Yalçin A, et al. Malnutrition-sarcopenia syndrome and all-cause mortality in hospitalized older people. Clin Nutr, 2021, 40(11):5475-5481.
[19] Tapper EB, Parikh ND.Diagnosis and management of cirrhosis and its complications: A review. JAMA, 2023,329(18):1589-1602.
[20] Abraldes JG, Caraceni P, Ghabril M, et al.Update in the treatment of the complications of dirrhosis. Clin Gastroenterol Hepatol,2023,21(8):2100-2109.

乙型肝炎肝硬化患者营养状况及肌少症发生率调查^*

Prevalence of nutrition and sarcopenia in patients with hepatitis B-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱中华, 胡均贤, 李炎. 索非布韦/达克拉韦治疗CHC患者血清血管性血友病因子和可溶性血管黏附因子1水平变化^*[J]. 实用肝脏病杂志, 2024, 27(6): 836-839.
[2]	董旭, 秦阳华, 廖威, 许明晓, 葛玲玲, 李成忠. 乙型肝炎肝硬化和慢加急性肝衰竭患者并发感染影响因素与预后分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 891-894.
[3]	陈思艳, 郭道宁, 邹晓攀, 漆家高. 彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 899-902.
[4]	马莉, 顾中盛, 李想. 内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 903-906.
[5]	邓娜, 郑玉凤, 刘旭红, 韩晓兵, 丁碧娇, 曾纬阳, 刘娜红, 黄莹, 陈梅桂. CT动态增强扫描诊断原发性肝癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 919-922.
[6]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[7]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.
[8]	信亮亮, 温智. 2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 737-740.
[9]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.
[10]	田琳, 康颖, 崔洁, 石颖鹏. 内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 745-748.
[11]	李双玲, 刘丽, 陈艺, 李坤. 富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 749-752.
[12]	连作勤, 王世明, 张甲, 李付平. 富马酸丙酚替诺福韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效和安全性评估^*[J]. 实用肝脏病杂志, 2024, 27(5): 753-756.
[13]	昝双江, 于恬, 戴静. 直接抗病毒药物治疗丙型肝炎肝硬化患者血清血小板生成素和外周血血小板计数变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 757-760.
[14]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[15]	任浩, 熊清芳. 多种无创检测指标预测自身免疫性肝病患者肝硬化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 535-538.